…The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
A Cochrane meta-analysis has examined 33 trials (n=1,518) to determine the benefits of physiotherapy versus no physiotherapy in patients with Parkinson’s disease (Tomlinson et al. Cochrane Database Syst Rev 2012 Aug 15;8:CD002817). Interventions included general physiotherapy, exercise, treadmill training, dance and martial arts. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you r…
…8, 2012 – The efficacy and safety of the oral fumarate BG-12 has been evaluated in the phase III studies DEFINE and CONFIRM (see BG-12 in RRMS: DEFINE trial, NeuroSens, October 21, 2011; CONFIRM – Second phase III trial results for BG-12, NeuroSens, November 30, 2011). New data from both trials were presented at AAN. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the…
…tinue…
…tshire et al. AAN 2012; abstract S02.007). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…